Cargando…
Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1
BACKGROUND: Lung adenocarcinoma (LUAD) is the leading cause of death among cancer diseases. The tumorigenic functions of AHNAK2 in LUAD have attracted more attention in recent years, while there are few studies which have reported its high molecular weight. METHODS: The mRNA‐seq data of AHNAK2 and c...
Autores principales: | Li, Xin, Li, Hui, Shao, Ming‐Ming, Miao, Jinbai, Fu, Yili, Hu, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396786/ https://www.ncbi.nlm.nih.gov/pubmed/37349884 http://dx.doi.org/10.1111/1759-7714.14989 |
Ejemplares similares
-
AHNAK2 is a biomarker and a potential therapeutic target of adenocarcinomas: AHNAK2 is a biomarker for adenocarcinomas
por: Xu, Meng, et al.
Publicado: (2022) -
Down-Regulation of AHNAK2 Inhibits Cell Proliferation, Migration and Invasion Through Inactivating the MAPK Pathway in Lung Adenocarcinoma
por: Wang, Dong-Wei, et al.
Publicado: (2020) -
AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma
por: Zhang, Shusen, et al.
Publicado: (2020) -
Cilia-associated cellular function of the AAA ATPases RUVBL1 and RUVBL2
por: Dafinger, Claudia, et al.
Publicado: (2015) -
Sorafenib as an Inhibitor of RUVBL2
por: Nano, Nardin, et al.
Publicado: (2020)